Left Ventricular Systolic Dysfunction

0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Abbott
AbbottABBOTT PARK, IL
1 program
SCD-HeFT 10 Year Follow-upN/A1 trial
Active Trials
NCT01058837Unknown1,855Est. Aug 2011
Astellas
AstellasChina - Shenyang
1 program
regadenosonN/A1 trial
Active Trials
NCT01842035CompletedEst. Jul 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Astellasregadenoson
AbbottSCD-HeFT 10 Year Follow-up

Clinical Trials (2)

Total enrollment: 1,855 patients across 2 trials

Heart Rate Response to Regadenoson and Sudden Cardiac Death

Start: Feb 2013Est. completion: Jul 2022
N/ACompleted
NCT01058837AbbottSCD-HeFT 10 Year Follow-up

SCD-HeFT 10 Year Follow-up

Start: Sep 2009Est. completion: Aug 20111,855 patients
N/AUnknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space